Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

The global lipid nanoparticles market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune responses were de novo, obser ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

A new hope in the fight against lung cancer is emerging with the launch of a clinical trial for an innovative vaccine. This vaccine, using messenger RNA (mRNA) technology, aims to train the ...

The global rna based therapeutics market  size is estimated to grow by USD 1.26 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  5.54%  during the ...

In 2020 their modified RNA technology became the key foundational component of the Pfizer/BioNTech and Moderna COVID-19 vaccines, which were deployed worldwide against the COVID-19 pandemic. [28] ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...